Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 70 out of 100. Cognitive tests and assessment

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Background Common genetic variance in apolipoprotein E (APOE), β-glucocerebrosidase (GBA), microtubule-associated protein tau (MAPT), and α-synuclein (SNCA) has been linked to cognitive decline in Parkinson's disease (PD), although studies have yielded mixed results. Objectives To evaluate the effect of genetic variants in APOE, GBA, MAPT, and SNCA on cognitive decline and risk of dementia in a pooled analysis of six longitudinal, non-selective, population-based cohorts of newly diagnosed PD patients. Methods 1002 PD patients, followed for up to 10 years (median 7.2 years), were genotyped for at least one of APOE-ε4, GBA mutations, MAPT H1/H2, or SNCA rs356219.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study of 281 participants. This pooled analysis of six population-based cohorts genotyped 1002 patients with newly diagnosed Parkinson's disease for APOE, GBA, MAPT, and SNCA variants and followed them for up to 10 years to assess cognitive decline and dementia risk. Reported effect size: 29.7%; 10.3%; HR 3.57.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Szwedo, A. A., Dalen, I., Pedersen, K. F., Camacho, M., Bäckström, D., Forsgren, L., et al. (2022). GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10-Year Population-Based Study. Movement disorders : official journal of the Movement Disorder Society. https://doi.org/10.1002/mds.28932

Vancouver

Szwedo AA, Dalen I, Pedersen KF, Camacho M, Bäckström D, Forsgren L, et al. GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10-Year Population-Based Study. Movement disorders : official journal of the Movement Disorder Society. 2022. doi:10.1002/mds.28932. PMID: 35106798.

BibTeX

@article{szwedo2022-35106798,
  author  = {Szwedo, A. A. and Dalen, I. and Pedersen, K. F. and Camacho, M. and Bäckström, D. and Forsgren, L. and Tzoulis, C. and Winder-Rhodes, S. and others},
  title   = {{GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10-Year Population-Based Study}},
  journal = {Movement disorders : official journal of the Movement Disorder Society},
  year    = {2022},
  doi     = {10.1002/mds.28932},
  pmid    = {35106798},
  url     = {https://doi.org/10.1002/mds.28932}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This pooled analysis of six population-based cohorts genotyped 1002 patients with newly diagnosed Parkinson's disease for APOE, GBA, MAPT, and SNCA variants and followed them for up to 10 years to assess cognitive decline and dementia risk. It examines genetic influences on cognitive decline in Parkinson's disease and does not test any treatment, cure, or prevention.

Study details

How this study scored 70/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 3 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 2 of 4; Effect reported 3 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 5 of 7; Citations per year 3 of 5; Impact for its field and year 4 of 6; Cited by studies here 2 of 6; Still being cited 3 of 4; Senior author's track record 2 of 4; Institution's track record 3 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 70 of 100.70 of 100 points earned30 not earned

Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Movement disorders : official journal of the Movement Disorder Society)
Journal's citation record 3 / 4 Movement Disorders: journal h-index 281 (OpenAlex, 2026-10-29)
Study design 7 / 12 A longitudinal study following the same people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2022 — within 6 year(s) of the newest study here
Sample size 2 / 4 281 participants
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 118 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 19.7 citations a year over 6 year(s) since 2022
Impact for its field and year 4 / 6 Cited 11.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 3 other studies in this library
Still being cited 3 / 4 Cited 74 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Jodi Maple‐Grødem: h-index 31 (OpenAlex, whole career)
Institution's track record 3 / 3 Harvard University: institution h-index 3,235 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 13 institution(s) in 5 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 35106798)
Free to read 2 / 2 Free to read
Total 70 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 19.

Later studies that cite this one

3 studies in the alzhub library list this one in their references.

Related studies in Cognitive tests and assessment from nearby years

Also tagged “lewy”

1,017 studies in the library carry the topic tag “lewy”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,017 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Cognitive tests and assessment

See all studies in Cognitive tests and assessment →